WO2005002561A1 - Antifungal agent composition for external use - Google Patents
Antifungal agent composition for external use Download PDFInfo
- Publication number
- WO2005002561A1 WO2005002561A1 PCT/JP2004/009411 JP2004009411W WO2005002561A1 WO 2005002561 A1 WO2005002561 A1 WO 2005002561A1 JP 2004009411 W JP2004009411 W JP 2004009411W WO 2005002561 A1 WO2005002561 A1 WO 2005002561A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- terbinafine hydrochloride
- external use
- preparation
- antifungal composition
- hydrochloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Definitions
- the present invention relates to an antifungal composition. More specifically, the present invention relates to an antifungal composition for external use in which the amount of terbinafine hydrochloride transferred to the keratin is improved.
- an antifungal agent that increases the concentration of drug in the stratum corneum immediately after application and maintains the level for a long time is ideal.
- a drug non-dissociated type
- a dissociated ionic type is superior in percutaneous absorbability and has a larger amount of exfoliated keratin than a dissociated ionic type.
- Terbinafine hydrochloride is a component used as an external antifungal agent because of its excellent pharmacological effect.
- Terbinafine hydrochloride like a general drug, is more advantageously dissolved and compounded as a molecular form in order to enhance the exfoliation of keratin.
- the pH of the antifungal composition for external use should be set to a neutral monoalkaline region exceeding the dissociation constant (pKa) of terbinafine hydrochloride 7.13. desirable.
- terbinafine hydrochloride has a very low solubility in a neutral monoalkaline preparation, so that it has been difficult to dissolve and mix it as a molecular form.
- Patent Document 1 a technique has been disclosed in which an antifungal agent is present in a dissolved state in a powder aerosol.
- Patent Document 1 JP-A-2000-229845
- An object of the present invention is to provide an external antifungal agent containing terbinafine hydrochloride having excellent keratin transfer properties.
- the present inventors have conducted various studies to provide a liquid preparation in which terbinafine hydrochloride is dissolved, which is a neutral mono-alkali liquid, and as a result, a lower alcohol and a polyol are simultaneously mixed, and the liquid property is specified. By limiting the range, it was found that terbinafine hydrochloride was dissolved in a molecular form and exhibited excellent exfoliation, and the present invention was completed.
- An external antifungal composition comprising terbinafine hydrochloride, a polyol, and a lower alcohol, wherein the liquidity of the preparation is in a neutral monoalkaline region.
- composition for external use wherein the polyol is one or more selected from the group consisting of polyethylene glycol, propylene glycol, 1,3-butylene glycol and glycerin.
- the content of terbinafine hydrochloride is 0.22 W / V in the whole preparation. 2.
- the compounding amount of terbinafine hydrochloride is preferably 0.22 W / V% of the whole preparation (in the case of an aerosol, in a stock solution), more preferably 0.5-1.5 W / V%. is there. 0.
- the content is less than 2 W / V%, the efficacy will be insufficient, and if the content is more than 2 W / V%, it will be difficult to provide a product with a high solubility.
- a lower alcohol is a straight-chain or branched-chain alcohol having 2 to 4 carbon atoms, which can be safely applied as an external preparation.
- Preferred lower alcohols Examples include ethanol and isopropanol, with ethanol being particularly preferred.
- the amount of the lower alcohol is preferably as large as possible in view of the solubility of terbinafine hydrochloride. However, if the lower alcohol is added in a large amount, irritation may occur at the time of application to the skin. Therefore, the blending amount of the lower alcohol is preferably 40-60 W / V%, more preferably 47 W / V% (60% by volume) and 56 W / V% (70% by volume).
- Preferable examples of the polyol to be blended in the present invention include polyethylene glycol (Macguchi Gal), propylene glycol, 1,3-butylene glycol, glycerin and the like.
- the amount of the polyol varies depending on the type and amount of the lower alcohol, and the amount of the polyol can be experimentally determined while confirming the dissolution of terbinafine hydrochloride. Also, if the polyol is added in a large amount, the stickiness at the time of application to the skin and the feeling of use will be very poor, so the usual compounding amount is 10-30 W / V of the whole preparation (in the case of aerosol, in the stock solution). %, Preferably 15-25 W / V%. Further, two or more kinds of polyols can be used in combination.
- ethanol is used as a lower alcohol, and when the compounding amount is 47.7 ⁇ //% (60% by volume) of the whole preparation, the compounding amount of the polyol is 25-30 W / V%, When the amount of ethanol is 55.7 W / V% (70% by volume), the amount of polyol is 10-30 W / V%.
- the pH of the drug product is in the region where terbinafine hydrochloride exists in a molecular form.
- the dissociation constant (pKa) is a neutral monoalkaline region exceeding 7.13. Force S. If the alkalinity is too strong, it will damage the skin. Therefore, the range of ⁇ 7.5 ⁇ 9 ⁇ 0 is preferable.
- composition of the present invention may be mixed with ordinary additives as necessary and prepared in an external manner such as a liquid, lotion, emulsion, tincture, cream, aqueous gel, aerosol, etc. Agent.
- FIG. 1 is a diagram showing the results of a keratin transfer test of terbinafine hydrochloride, with the vertical axis showing keratin transfer. The application time was shown on the horizontal axis of the row ratio (%).
- a lotion was prepared by a conventional method (the pH of Synthetic IJ was adjusted to about 8 with diisopropanolamine).
- Purified water total lOOmL A lotion was prepared according to the above formulation by a conventional method (the pH of the preparation was adjusted to about 8 with sodium hydroxide).
- the carboxyvinyl polymer was dissolved in water and propylene glycol, and allowed to stand at room temperature to swell the propyloxyvinyl polymer. Ethanol, terbinafine hydrochloride, lidocaine and EDTA-2Na were added thereto. Further, diisopropanolamine was added to adjust the pH of the preparation to about 8, thereby producing a gel.
- a lotion was prepared using the above formulation in a conventional manner (the pH of the formulation was adjusted to about 8 with sodium hydroxide).
- a lotion was prepared according to the above formulation by a conventional method (the pH of the preparation was adjusted to about 5 with sodium hydroxide).
- a lotion was prepared according to the above formulation by a conventional method (the pH of the preparation was adjusted to about 8 with diisopropanolamine).
- a lotion was prepared according to the above formulation by a conventional method (the pH of the preparation was adjusted to about 8 with sodium hydroxide).
- Petano 1 50 g Diisopropanolamine qs
- a lotion was prepared according to the above formulation by a conventional method (the pH of the preparation was adjusted to about 8 with diisopropanolamine).
- a lotion was prepared according to the above formulation by a conventional method (the pH of the preparation was adjusted to about 8 with diisopropanolamine).
- Polyethylene glycol 400 10.0 g
- Petano 1 50 g Diisopropanolamine qs
- a mouthwash was prepared by a conventional method (the pH of the formulation was adjusted to about 8 with diisopropanolamine).
- terbinafine hydrochloride usually has extremely poor solubility at a pH of more than pKa 7.13, but the formulation of the present invention has a terbinafine hydrochloride even at a pH of 7.5 or more. It was possible to dissolve naphine (1% by weight).
- Test Example 2 Test of terbinafine hydrochloride transfer to keratin rats
- a hairless rat (Claire Nippon, male, 11-15 weeks old) was fixed in the dorsal position, and the abdomen was electrically sheathed. After removing the hair, the dirt was wiped off. 20 Ai L of each sample (Example 5 and Comparative Example 1) was weighed with a micropipette and uniformly applied to the abdomen (1.8 ⁇ 2.5 cm). Six hours after application or 24 hours after application, the sample remaining on the skin surface was sufficiently wiped off using absorbent cotton impregnated with 70% ethanol. Thereafter, a commercially available pressure-sensitive adhesive tape was stuck to the application site, and pressure-bonded to peel off the stratum corneum. This stratum corneum peeling operation was repeated 10 times. Terbinafine hydrochloride was extracted from 10 adhesive tapes used for peeling the stratum corneum with methanol, and the amount of exfoliated keratin was measured by high performance liquid chromatography.
- FIG. 1 shows the results. The results are the average of three tests for each sample.
- Example 5 in which the pH was adjusted to 8 exhibited higher exfoliating properties than the preparation of Comparative Example 1 in which the pH was adjusted to 5.
- the present invention can be used as a therapeutic agent for athlete's foot, cotton beetle, common bug or tinea unguium.
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
明 細 書 Specification
外用抗真菌剤組成物 External antifungal composition
技術分野 Technical field
[0001] 本発明は、抗真菌剤組成物に関する。さらに、詳しくは塩酸テルビナフインの角質 移行量を向上させた外用抗真菌剤組成物に関する。 The present invention relates to an antifungal composition. More specifically, the present invention relates to an antifungal composition for external use in which the amount of terbinafine hydrochloride transferred to the keratin is improved.
背景技術 Background art
[0002] 真菌は皮膚角質層で増殖するため、抗真菌剤が効力を発生するには抗真菌活性 、抗菌スぺ外ルだけでなぐ真菌の生息部位である角質層における薬物濃度が重 要である。 [0002] Since fungi multiply in the stratum corneum of the skin, antifungal activity and the drug concentration in the stratum corneum, which is a site where fungi inhabit only by the antibacterial agent, are important for the antifungal agent to be effective. is there.
[0003] 抗真菌剤としては、塗布後速やかに角質内薬物濃度が高まり、そのレベルが長時 間維持されるものが理想的である。 [0003] As an antifungal agent, an antifungal agent that increases the concentration of drug in the stratum corneum immediately after application and maintains the level for a long time is ideal.
[0004] 一般的に、薬物は解離したイオン型より分子型 (非解離型)の方が経皮吸収性に優 れ、角質移行量も多いことが知られている。 [0004] In general, it is known that a drug (non-dissociated type) is superior in percutaneous absorbability and has a larger amount of exfoliated keratin than a dissociated ionic type.
[0005] 塩酸テルビナフインは、優れた薬理効果から外用抗真菌剤として使用されている成 分である。 [0005] Terbinafine hydrochloride is a component used as an external antifungal agent because of its excellent pharmacological effect.
[0006] 塩酸テルビナフインも一般的な薬物同様、角質移行性を高めるためには分子型とし て溶解配合する方が有利である。 [0006] Terbinafine hydrochloride, like a general drug, is more advantageously dissolved and compounded as a molecular form in order to enhance the exfoliation of keratin.
[0007] 塩酸テルビナフインを分子型として溶解配合するためには、外用抗真菌剤組成物 の pHは塩酸テルビナフインの解離定数(pKa) 7. 13を超える、中性一アルカリ性領 域に設定することが望ましい。 [0007] In order to dissolve and mix terbinafine hydrochloride as a molecular form, the pH of the antifungal composition for external use should be set to a neutral monoalkaline region exceeding the dissociation constant (pKa) of terbinafine hydrochloride 7.13. desirable.
[0008] し力、しながら、塩酸テルビナフインは中性一アルカリ性製剤中での溶解性が極めて 低いため、分子型として溶解配合することは困難であった。 [0008] However, terbinafine hydrochloride has a very low solubility in a neutral monoalkaline preparation, so that it has been difficult to dissolve and mix it as a molecular form.
[0009] 従来、粉末エアゾール中で抗真菌剤を溶解状態で存在させる技術は開示されてい る(特許文献 1)。 Conventionally, a technique has been disclosed in which an antifungal agent is present in a dissolved state in a powder aerosol (Patent Document 1).
[0010] 特許文献 1 :特開 2000-229845 Patent Document 1: JP-A-2000-229845
発明の開示 Disclosure of the invention
発明が解決しょうとする課題 [0011] 本発明は、優れた角質移行性を有する塩酸テルビナフイン含有外用抗真菌剤を提 供することを目的とする。 Problems the invention is trying to solve [0011] An object of the present invention is to provide an external antifungal agent containing terbinafine hydrochloride having excellent keratin transfer properties.
課題を解決するための手段 Means for solving the problem
[0012] 本発明者らは、中性一アルカリ性の液性で、塩酸テルビナフインが溶解された液剤 を提供するため種々検討した結果、低級アルコールとポリオールを同時に配合し、そ の液性を特定の範囲に限定することにより、塩酸テルビナフインを分子型として溶解 させ、優れた角質移行性を示すことを見出し、本発明を完成した。 [0012] The present inventors have conducted various studies to provide a liquid preparation in which terbinafine hydrochloride is dissolved, which is a neutral mono-alkali liquid, and as a result, a lower alcohol and a polyol are simultaneously mixed, and the liquid property is specified. By limiting the range, it was found that terbinafine hydrochloride was dissolved in a molecular form and exhibited excellent exfoliation, and the present invention was completed.
[0013] すなわち、本発明は、 [0013] That is, the present invention provides
(1)塩酸テルビナフイン、ポリオールおよび低級アルコールを配合し、製剤の液性が 中性一アルカリ性の領域である外用抗真菌剤組成物。 (1) An external antifungal composition comprising terbinafine hydrochloride, a polyol, and a lower alcohol, wherein the liquidity of the preparation is in a neutral monoalkaline region.
(2)ポリオールがポリエチレングリコール、プロピレングリコール、 1,3-ブチレングリコ ールおよびグリセリンからなる群から選ばれる 1種または 2種以上である(1)に記載の 外用抗真菌剤組成物。 (2) The antifungal composition for external use according to (1), wherein the polyol is one or more selected from the group consisting of polyethylene glycol, propylene glycol, 1,3-butylene glycol and glycerin.
(3)ポリオールの配合量が製剤全体の 10— 30W/V%である(1)に記載の外用抗真 菌剤組成物。 (3) The antifungal composition for external use according to (1), wherein the blending amount of the polyol is 10 to 30 W / V% of the whole preparation.
(4)低級アルコールがエタノールである(1)に記載の外用抗真菌剤組成物。 (4) The antifungal composition for external use according to (1), wherein the lower alcohol is ethanol.
(5)エタノールの配合量力 S47— 56W/V%である(4)に記載の外用抗真菌剤組成物 (5) The antifungal composition for external use according to (4), wherein the compounding power of ethanol is S47-56 W / V%.
(6)塩酸テルビナフインの配合量が製剤全体の 0. 2 2W/V。/oである(1)に記載の 外用抗真菌剤組成物。 (6) The content of terbinafine hydrochloride is 0.22 W / V in the whole preparation. 2. The antifungal composition for external use according to (1), wherein the composition is / o.
(7)製剤の pHが 7. 5-9. 0である(1)に記載の外用抗真菌剤組成物。 (7) The antifungal composition for external use according to (1), wherein the pH of the preparation is 7.5-9.0.
である。 It is.
[0014] 本発明において、塩酸テルビナフインの配合量は、製剤全体(エアゾールの場合は 原液中)の 0. 2 2W/V%が好ましぐさらに好ましくは 0. 5- 1. 5W/V%である。 0. [0014] In the present invention, the compounding amount of terbinafine hydrochloride is preferably 0.22 W / V% of the whole preparation (in the case of an aerosol, in a stock solution), more preferably 0.5-1.5 W / V%. is there. 0.
2W/V%未満であると効力が不十分になり、 2W/V%を超えて配合すると溶解度の点 力 製品として提供することが難しいからである。 If the content is less than 2 W / V%, the efficacy will be insufficient, and if the content is more than 2 W / V%, it will be difficult to provide a product with a high solubility.
[0015] 本発明で、低級アルコールとは炭素原子数 2— 4の直鎖状、分岐鎖状のアルコー ルで、外用剤として安全に塗布できるもののことである。好ましい低級アルコールとし ては、エタノールおよびイソプロパノールがあげられ、エタノールが特に好ましい。 [0015] In the present invention, a lower alcohol is a straight-chain or branched-chain alcohol having 2 to 4 carbon atoms, which can be safely applied as an external preparation. Preferred lower alcohols Examples include ethanol and isopropanol, with ethanol being particularly preferred.
[0016] 低級アルコールの配合量は、塩酸テルビナフインの溶解度の点では多いほど好ま しいが、低級アルコールを多量に配合しすぎると、皮膚塗布時に刺激を生じる可能 性がある。したがって、低級アルコールの配合量は 40— 60W/V%が好ましぐ 47 W/V% (60体積%) 56W/V% (70体積%)がさらに好ましい。 [0016] The amount of the lower alcohol is preferably as large as possible in view of the solubility of terbinafine hydrochloride. However, if the lower alcohol is added in a large amount, irritation may occur at the time of application to the skin. Therefore, the blending amount of the lower alcohol is preferably 40-60 W / V%, more preferably 47 W / V% (60% by volume) and 56 W / V% (70% by volume).
[0017] 本発明で配合するポリオールの好ましいものとしては、ポリエチレングリコール(マク 口ゴール)、プロピレングリコール、 1,3 -ブチレングリコール、グリセリンなどがあげられ る。 [0017] Preferable examples of the polyol to be blended in the present invention include polyethylene glycol (Macguchi Gal), propylene glycol, 1,3-butylene glycol, glycerin and the like.
[0018] 本発明においてポリオールの配合量は、低級アルコールの種類と配合量により変 化し、塩酸テルビナフインの溶解を確認しながら実験的に配合量を決定することがで きる。また、ポリオールを多量に配合しすぎると、皮膚塗布時にベたつき、使用感が 非常に悪くなるため、通常の配合量は、製剤全体 (エアゾールの場合は原液中)の 1 0— 30W/V%であり、好ましくは 15— 25W/V%である。また、 2種類以上のポリオ一 ルを混合して用いることもできる。ここで、例として低級アルコールにエタノールを用い 、配合量が製剤全体の 47. 7\¥/¥% (60体積%)の場合にはポリオールの配合量は 2 5— 30W/V%であり、エタノールの配合量が 55· 7W/V% (70体積%)の場合にはポ リオールの配合量は 10— 30W/V%である。 In the present invention, the amount of the polyol varies depending on the type and amount of the lower alcohol, and the amount of the polyol can be experimentally determined while confirming the dissolution of terbinafine hydrochloride. Also, if the polyol is added in a large amount, the stickiness at the time of application to the skin and the feeling of use will be very poor, so the usual compounding amount is 10-30 W / V of the whole preparation (in the case of aerosol, in the stock solution). %, Preferably 15-25 W / V%. Further, two or more kinds of polyols can be used in combination. Here, as an example, ethanol is used as a lower alcohol, and when the compounding amount is 47.7 \ //% (60% by volume) of the whole preparation, the compounding amount of the polyol is 25-30 W / V%, When the amount of ethanol is 55.7 W / V% (70% by volume), the amount of polyol is 10-30 W / V%.
[0019] 製剤の pHは塩酸テルビナフインが分子型で存在する領域であり、解離定数 (pKa) 7. 13を超える中性一アルカリ性領域である力 S、アルカリ性が強すぎると、皮膚にダメ ージを与えるため、 ρΗ7· 5— 9· 0の範囲が好ましい。 [0019] The pH of the drug product is in the region where terbinafine hydrochloride exists in a molecular form. The dissociation constant (pKa) is a neutral monoalkaline region exceeding 7.13. Force S. If the alkalinity is too strong, it will damage the skin. Therefore, the range of ρΗ7.5 · 9 · 0 is preferable.
[0020] 本発明の組成物は、必要に応じて通常の添加剤などを混合して常法により、液剤、 ローション剤、乳剤、チンキ剤、クリーム剤、水性ゲル剤、エアゾール剤などの外用製 剤とすることができる。 [0020] The composition of the present invention may be mixed with ordinary additives as necessary and prepared in an external manner such as a liquid, lotion, emulsion, tincture, cream, aqueous gel, aerosol, etc. Agent.
発明の効果 The invention's effect
[0021] 本発明により、塩酸テルビナフインの角質移行性をより高めることができ、皮膚糸状 菌に対して極めて効力の強い抗真菌剤を提供することが可能になった。 According to the present invention, it has become possible to further enhance the keratin transfer of terbinafine hydrochloride, and to provide an antifungal agent which is extremely effective against dermatophytes.
図面の簡単な説明 Brief Description of Drawings
[0022] [図 1]塩酸テルビナフインの角質移行性試験の結果を示した図であり、縦軸に角質移 行率(%)横軸に塗布時間を示した。 FIG. 1 is a diagram showing the results of a keratin transfer test of terbinafine hydrochloride, with the vertical axis showing keratin transfer. The application time was shown on the horizontal axis of the row ratio (%).
発明を実施するための最良の形態 BEST MODE FOR CARRYING OUT THE INVENTION
[0023] 以下実施例および試験例により、本発明を詳細に説明する。 Hereinafter, the present invention will be described in detail with reference to Examples and Test Examples.
実施例 1 Example 1
[0024] (ローション) [0024] (Lotion)
塩酸テルビナフイン 1. Og Terbinafine hydrochloride 1. Og
塩化ベンザルコニゥム 0· 05g Benzalkonium chloride 0 ・ 05g
グリチルリチン酸二カリウム 0· 5g Dipotassium glycyrrhizinate 0.5g
1一メントール 1. Og 1 menthol 1. Og
ポジエチレングリコーノレ 400 20. Og Posiethylene glycolone 400 20.Og
ヱタノ一ノレ 50. Og ヱ ノ 50 50. Og
BHT 0. 05g BHT 0.05 g
ジイソプロパノールァミン 適量 Diisopropanolamine qs
精製水 全 lOOmL Purified water total lOOmL
上記処方で、常法によりローション剤を製造した(ジイソプロパノールァミンにて製斉 IJ の pHを約 8に調整した)。 With the above formulation, a lotion was prepared by a conventional method (the pH of Synthetic IJ was adjusted to about 8 with diisopropanolamine).
実施例 2 Example 2
[0025] (ローション) [0025] (Lotion)
塩酸テルビナフイン 1 · Og Terbinafine hydrochloride 1 · Og
リドカイン 2. Og Lidocaine 2. Og
塩化デカリニゥム 0. lg Decalinium chloride 0.1 lg
グリチルリチン酸二カリウム 0. 5g 0.5 g of dipotassium glycyrrhizinate
トメントーノレ 1. 0g Tomentonore 1.0g
ポリエチレングリコーノレ 400 20. 0g Polyethylene glycolone 400 20.0 g
ヱタノ一ノレ 50. 0g Petano 1 50 g
BHT 0. 05g BHT 0.05 g
水酸化ナトリウム 適量 Sodium hydroxide
精製水 全 lOOmL 上記処方で、常法によりローション剤を製造した (水酸化ナトリウムにて製剤の pHを 約 8に調整した)。 Purified water total lOOmL A lotion was prepared according to the above formulation by a conventional method (the pH of the preparation was adjusted to about 8 with sodium hydroxide).
実施例 3 Example 3
(ゲル剤) (Gel)
塩酸テルビナフイン 1. Og Terbinafine hydrochloride 1. Og
リドカイン 2. Og Lidocaine 2. Og
プロピレングリコーノレ 15. Og Propylene glycolone 15.Og
カノレボキシビ二/レポリマー 1. Og Canoleboxivini / Repolymer 1. Og
EDTA-2Na 0. lg EDTA-2Na 0.lg
エタノーノレ 50. Og Ethanore 50. Og
ジイソプロパノールァミン 適量 Diisopropanolamine qs
精製水 全 lOOg Purified water total lOOg
水、プロピレングリコールにカルボキシビ二ルポリマーを溶解し、室温で放置し、力 ルポキシビ二ルポリマーを膨潤させた。これにエタノール、塩酸テルビナフイン、リドカ インおよび EDTA— 2Naを添加した。さらにジイソプロパノールアミンを加え、製剤の p Hを約 8に調整し、ゲルを製造した。 The carboxyvinyl polymer was dissolved in water and propylene glycol, and allowed to stand at room temperature to swell the propyloxyvinyl polymer. Ethanol, terbinafine hydrochloride, lidocaine and EDTA-2Na were added thereto. Further, diisopropanolamine was added to adjust the pH of the preparation to about 8, thereby producing a gel.
実施例 4 Example 4
(エアゾール剤) (Aerosol)
原液: Stock solution:
塩酸テルビナフイン 1. Og Terbinafine hydrochloride 1. Og
塩ィ匕ベンザノレ ニクム 0. 05g Shio-Dani Benzanore Nicum 0.05g
グリチルリチン酸二カリウム 0. 5g 0.5 g of dipotassium glycyrrhizinate
1 , 3ブチレングリコール 20. 0g 1,3 butylene glycol 20.0 g
エタノーノレ 50. 0g Ethanore 50.0 g
ジイソプロパノールァミン 適量 Diisopropanolamine qs
精製水 全 lOOmL Purified water total lOOmL
噴射剤: Propellant:
DME 50mL エタノール、精製水の基剤に他の原液成分を溶解後、ジイソプロパノールァミンに て製剤の pHを約 8に調整し、原液を製造した。容器に充填後、バルブを装着し、噴 射剤を充填してエアゾール剤を製造した。 DME 50mL After dissolving the other stock solutions in ethanol and purified water base, the pH of the formulation was adjusted to about 8 with diisopropanolamine to prepare stock solutions. After filling the container, a valve was attached and the propellant was filled to produce an aerosol.
実施例 5 Example 5
[0028] (ローション) [0028] (Lotion)
塩酸テルビナフイン 1. Og Terbinafine hydrochloride 1. Og
ポリエチレングリコール 400 25. Og Polyethylene glycol 400 25.Og
エタノーノレ 47· 7g Ethanorne 47g
水酸化ナトリウム 適量 Sodium hydroxide
精製水 全 lOOmL Purified water total lOOmL
上記処方で、常法によりローション剤を製造した (水酸化ナトリウムにて製剤の pHを 約 8に調整した)。 A lotion was prepared using the above formulation in a conventional manner (the pH of the formulation was adjusted to about 8 with sodium hydroxide).
[0029] 比較例 1 [0029] Comparative Example 1
(ローション) (Lotion)
塩酸テルビナフイン 1. Og Terbinafine hydrochloride 1. Og
ポリエチレングリコーノレ 400 25. Og Polyethylene glycolone 400 25.Og
エタノーノレ 47. 7g Ethanore 47.7 g
水酸化ナトリウム 適量 Sodium hydroxide
精製水 全 lOOmL Purified water total lOOmL
上記処方で、常法によりローション剤を製造した (水酸化ナトリウムにて製剤の pHを 約 5に調整した)。 A lotion was prepared according to the above formulation by a conventional method (the pH of the preparation was adjusted to about 5 with sodium hydroxide).
実施例 6 Example 6
[0030] (ローション) [0030] (Lotion)
塩酸テルビナフイン 1. Og Terbinafine hydrochloride 1. Og
2. Og 2. Og
塩化ベンザルコニゥム 0. 05g Benzalkonium chloride 0.05 g
ダリチノレリチン酸二カリウム 0. 5g 0.5 g of dipotassium dalitinoleritinate
1一メントール 1. Og 1 , 3ブチレングリコール 10. 0g 1 menthol 1. Og 1,3 butylene glycol 10.0 g
エタノーノレ 55. 0g Ethanore 55.0 g
ジイソプロパノールァミン 適量 Diisopropanolamine qs
精製水 全 100mし 100m of purified water
上記処方で、常法によりローション剤を製造した(ジイソプロパノールァミンにて製剤 の pHを約 8に調整した)。 A lotion was prepared according to the above formulation by a conventional method (the pH of the preparation was adjusted to about 8 with diisopropanolamine).
実施例 7 Example 7
[0031] (ローション) [0031] (Lotion)
塩酸テルビナフイン 1. 0g Terbinafine hydrochloride 1.0 g
ジブ力イン 0· 5g Jib force in 0.5g
塩化べンゼトニゥム 0. 5g Benzetonium chloride 0.5 g
グリチルリチン酸二カリウム 0. 5g 0.5 g of dipotassium glycyrrhizinate
1—メン卜一ノレ 1. 0g 1—mentoring 1.0 g
1 , 3ブチレングリコール 20. 0g 1,3 butylene glycol 20.0 g
エタノーノレ 50. 0g Ethanore 50.0 g
水酸化ナトリウム 適量 Sodium hydroxide
精製水 全 lOOmL Purified water total lOOmL
上記処方で、常法によりローション剤を製造した (水酸化ナトリウムにて製剤の pHを 約 8に調整した)。 A lotion was prepared according to the above formulation by a conventional method (the pH of the preparation was adjusted to about 8 with sodium hydroxide).
実施例 8 Example 8
[0032] (ローション) [0032] (Lotion)
塩酸テルビナフイン 1. 0g Terbinafine hydrochloride 1.0 g
塩酸リドカイン 2. 0g Lidocaine hydrochloride 2.0 g
塩化べンゼトニゥム 0. 5g Benzetonium chloride 0.5 g
グリチルリチン酸二カリウム 0. 5g 0.5 g of dipotassium glycyrrhizinate
1—メン卜一ノレ 1. 0g 1—mentoring 1.0 g
プロピレングリコーノレ 20. 0g Propylene glycolonole 20.0 g
ヱタノ一ノレ 50. 0g ジイソプロパノールァミン 適量 Petano 1 50 g Diisopropanolamine qs
精製水 全 lOOmL Purified water total lOOmL
上記処方で、常法によりローション剤を製造した(ジイソプロパノールァミンにて製剤 の pHを約 8に調整した)。 A lotion was prepared according to the above formulation by a conventional method (the pH of the preparation was adjusted to about 8 with diisopropanolamine).
実施例 9 Example 9
[0033] (ローション) [0033] (Lotion)
塩酸テルビナフイン 1. Og Terbinafine hydrochloride 1. Og
リドカイン 2· Og Lidocaine 2 Og
塩ィ匕ベンザノレ ニクム 0. 05g Shio-Dani Benzanore Nicum 0.05g
グリチルリチン酸二カリウム 0. 5g 0.5 g of dipotassium glycyrrhizinate
1—メン卜一ノレ 1. Og 1—Mention 1.Og
1 , 3ブチレングリコール 10. Og 1,3 butylene glycol 10.Og
エタノーノレ 45. 0g Ethanore 45.0g
イソプロピルアルコール 10. 0g Isopropyl alcohol 10.0 g
ジイソプロパノールァミン 適量 Diisopropanolamine qs
精製水 全 lOOmL Purified water total lOOmL
上記処方で、常法によりローション剤を製造した(ジイソプロパノールァミンにて製剤 の pHを約 8に調整した)。 A lotion was prepared according to the above formulation by a conventional method (the pH of the preparation was adjusted to about 8 with diisopropanolamine).
実施例 10 Example 10
[0034] (ローション) [0034] (Lotion)
塩酸テルビナフイン 1. Og Terbinafine hydrochloride 1. Og
リドカイン 2· Og Lidocaine 2 Og
塩化デカリニゥム 0. lg Decalinium chloride 0.1 lg
グリチルリチン酸二カリウム 0. 5g 0.5 g of dipotassium glycyrrhizinate
1—メン卜一ノレ 1. Og 1—Mention 1.Og
1 , 3ブチレングリコール 10. Og 1,3 butylene glycol 10.Og
ポリエチレングリコール 400 10. 0g Polyethylene glycol 400 10.0 g
ヱタノ一ノレ 50. 0g ジイソプロパノールァミン 適量 Petano 1 50 g Diisopropanolamine qs
精製水 全 100mし 100m of purified water
上記処方で、常法により口ーシヨン剤を製造した(ジイソプロパノールァミンにて製剤 の pHを約 8に調整した)。 With the above formulation, a mouthwash was prepared by a conventional method (the pH of the formulation was adjusted to about 8 with diisopropanolamine).
[0035] 試験例 1 Test Example 1
塩酸テルビナフインの溶解性試験 Solubility test of terbinafine hydrochloride
(試験方法) (Test method)
「水:エタノール: PEG400」比率の異なる溶液への塩酸テルビナフイン(1W/V%) の溶解性を目視により確認した。なお、 pHは水酸化ナトリウムにより調整した。 The solubility of terbinafine hydrochloride (1 W / V%) in solutions having different “water: ethanol: PEG400” ratios was visually confirmed. The pH was adjusted with sodium hydroxide.
[0036] 表 1にエタノーノレ 39. 8重量%(50体積0 /0)配合処方における PEG400配合量に 対する塩酸テルビナフインの溶解性、表 2にエタノール 47. 7重量%(60体積%)配 合処方における PEG400配合量に対する塩酸テルビナフインの溶解性、表 3にエタ ノーノレ 55. 7重量% (70体積%)配合処方における PEG400配合量に対する塩酸テ ルビナフインの溶解性をそれぞれ示した。なお、表中〇は溶解し、 Xは溶解しなかつ たことを示す。 [0036] Table 1 Etanonore 39.8 wt% (50 vol 0/0) solubility of hydrochloric Terubinafuin against the PEG400 amount in formulation, ethanol 47.7 wt% in Table 2 (60 vol%) Blend Formulation Table 3 shows the solubility of terbinafine hydrochloride with respect to the amount of PEG400 in Table 3, and Table 3 shows the solubility of terbinafine hydrochloride with respect to the amount of PEG400 in a formulation containing 55.7% by weight (70% by volume) of ethanol. In the table, 〇 indicates that it was dissolved, and X indicates that it was not dissolved.
[0037] [表 1] [Table 1]
10 , 0 X X X X 10, 0 X X X X
9 . 5 X X X X 9.5 X X X X
9 . 0 X X X X 9.0 X X X X
8 . 5 X X X X 8.5 X X X X
8 . 0 X X X X 8.0 X X X X
7 . 5 X X X X 7.5 X X X X
7 . 0 X X X X 7.0 X X X X
8 . B X X X X 8. B X X X X
8 , 0 X X o o 8, 0 X X o o
B , 5 X o o O B, 5 X o o O
5 , 0 o O O O 5, 0 o O O O
4 . 5 O リ O o 4.5 O O O O
0 1 0 2 0 0 1 0 2 0
P E G 400 K合重 (簠置%) P E G 400 K combined weight (location%)
[0038] [表 2] [Table 2]
Ρ Ε G 400配合量 (鬣曩%) 400 Ε G 400 compounding amount (mane stalk%)
[0039] [表 3] [Table 3]
P E G 400配合置 (重 ¾ % ) P E G 400 compounding (weight%)
[0040] 表から明らかなように、通常、塩酸テルビナフインは pKa7. 13を超える pH以上で の溶解性は極めて悪レ、が、本発明の処方は、 pH7. 5以上であっても、塩酸テルビ ナフイン(1重量%)を溶解することが可能であった。 [0040] As is clear from the table, terbinafine hydrochloride usually has extremely poor solubility at a pH of more than pKa 7.13, but the formulation of the present invention has a terbinafine hydrochloride even at a pH of 7.5 or more. It was possible to dissolve naphine (1% by weight).
[0041] 試験例 2 (塩酸テルビナフインのへアレスラット角質移行性試験) Test Example 2 (Test of terbinafine hydrochloride transfer to keratin rats)
(実験方法) (experimental method)
ヘアレスラット(日本クレア,雄, 11一 15週齢)を背位固定し、腹部を電気シエーバ 一で除毛後、汚れをふき取った。各サンプル (実施例 5および比較例 1) 20 Ai Lをマイ クロピペットで量り、腹部(1. 8 X 2. 5cm)に均一に塗布した。塗布 6時間後または塗 布 24時間後に、 70%エタノールを染み込ませた脱脂綿を用いて皮膚表面に残存す るサンプルを十分に拭き取った。その後、塗布部位に市販の粘着テープを貼付し、 圧着して角質層を剥離した。この角質層剥離操作を 10回繰り返した。角質層の剥離 に用いた粘着テープ 10枚からメタノールにより塩酸テルビナフインを抽出し、高速液 体クロマトグラフィーで角質移行量を測定した。 A hairless rat (Claire Nippon, male, 11-15 weeks old) was fixed in the dorsal position, and the abdomen was electrically sheathed. After removing the hair, the dirt was wiped off. 20 Ai L of each sample (Example 5 and Comparative Example 1) was weighed with a micropipette and uniformly applied to the abdomen (1.8 × 2.5 cm). Six hours after application or 24 hours after application, the sample remaining on the skin surface was sufficiently wiped off using absorbent cotton impregnated with 70% ethanol. Thereafter, a commercially available pressure-sensitive adhesive tape was stuck to the application site, and pressure-bonded to peel off the stratum corneum. This stratum corneum peeling operation was repeated 10 times. Terbinafine hydrochloride was extracted from 10 adhesive tapes used for peeling the stratum corneum with methanol, and the amount of exfoliated keratin was measured by high performance liquid chromatography.
[0042] 結果を図 1に示した。なお、結果は各試料について試験を 3回行った平均値である FIG. 1 shows the results. The results are the average of three tests for each sample.
[0043] 図 1から明らかなように、 pHを 8に調整した実施例 5の製剤は、 pHを 5に調整した比 較例 1の製剤よりも高い角質移行性を示すことが確認された。 As is clear from FIG. 1, it was confirmed that the preparation of Example 5 in which the pH was adjusted to 8 exhibited higher exfoliating properties than the preparation of Comparative Example 1 in which the pH was adjusted to 5.
産業上の利用可能性 Industrial applicability
[0044] 本発明は、水虫、いんきんたむし、ぜにたむしまたは爪白癬の治療薬として利用可 能である。 [0044] The present invention can be used as a therapeutic agent for athlete's foot, cotton beetle, common bug or tinea unguium.
Claims
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005511357A JP5435836B2 (en) | 2003-07-03 | 2004-07-02 | Antifungal composition for external use |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003191271 | 2003-07-03 | ||
| JP2003-191271 | 2003-07-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2005002561A1 true WO2005002561A1 (en) | 2005-01-13 |
Family
ID=33562353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2004/009411 Ceased WO2005002561A1 (en) | 2003-07-03 | 2004-07-02 | Antifungal agent composition for external use |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP5435836B2 (en) |
| WO (1) | WO2005002561A1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006131597A (en) * | 2004-11-09 | 2006-05-25 | Hisamitsu Pharmaceut Co Inc | Aerosol composition |
| WO2010086727A1 (en) * | 2009-01-30 | 2010-08-05 | Galderma Pharma Sa | Stable compositions for nail onychomycosis treatment |
| JP2019006710A (en) * | 2017-06-26 | 2019-01-17 | 小林製薬株式会社 | Aqueous preparation |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016144121A2 (en) * | 2015-03-12 | 2016-09-15 | 동아제약 주식회사 | Pharmaceutical composition for treating fungal infectious diseases of ketratin tissue |
| KR101690765B1 (en) * | 2015-04-17 | 2016-12-28 | 동아제약 주식회사 | Transdermal formulation comprising antifungal agent |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0585929A (en) * | 1991-03-08 | 1993-04-06 | L'oreal Sa | Use of hydrophilic penetrants in dermatological compositions for the treatment of onychomycosis and corresponding compositions |
| JPH05132419A (en) * | 1991-05-20 | 1993-05-28 | Sandoz Ag | Medicinal composition |
| WO2000038731A1 (en) * | 1998-12-28 | 2000-07-06 | Taisho Pharmaceutical Co.,Ltd. | External preparation |
| JP2001518879A (en) * | 1997-03-31 | 2001-10-16 | ジョンソン・アンド・ジョンソン・コンシューマー・カンパニーズ・インコーポレイテッド | Solvent system for improved penetration of drug compounds |
-
2004
- 2004-07-02 WO PCT/JP2004/009411 patent/WO2005002561A1/en not_active Ceased
- 2004-07-02 JP JP2005511357A patent/JP5435836B2/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0585929A (en) * | 1991-03-08 | 1993-04-06 | L'oreal Sa | Use of hydrophilic penetrants in dermatological compositions for the treatment of onychomycosis and corresponding compositions |
| JPH05132419A (en) * | 1991-05-20 | 1993-05-28 | Sandoz Ag | Medicinal composition |
| JP2001518879A (en) * | 1997-03-31 | 2001-10-16 | ジョンソン・アンド・ジョンソン・コンシューマー・カンパニーズ・インコーポレイテッド | Solvent system for improved penetration of drug compounds |
| WO2000038731A1 (en) * | 1998-12-28 | 2000-07-06 | Taisho Pharmaceutical Co.,Ltd. | External preparation |
Non-Patent Citations (1)
| Title |
|---|
| PETRANYI G. ET AL.: "Antifungal activity of the allylamine derivative terbinafine in vitro", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 31, no. 9, September 1987 (1987-09-01), pages 1365 - 1368, XP002980982 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006131597A (en) * | 2004-11-09 | 2006-05-25 | Hisamitsu Pharmaceut Co Inc | Aerosol composition |
| WO2010086727A1 (en) * | 2009-01-30 | 2010-08-05 | Galderma Pharma Sa | Stable compositions for nail onychomycosis treatment |
| JP2019006710A (en) * | 2017-06-26 | 2019-01-17 | 小林製薬株式会社 | Aqueous preparation |
| JP7198573B2 (en) | 2017-06-26 | 2023-01-04 | 小林製薬株式会社 | Aqueous formulation |
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2005002561A1 (en) | 2006-10-19 |
| JP5435836B2 (en) | 2014-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3081766B2 (en) | Keratin storage type antifungal external composition | |
| US20080138391A1 (en) | Skin-friendly drug complexes for transdermal administration | |
| TW413637B (en) | Preparation for percutaneous absorption | |
| JPH0325406B2 (en) | ||
| JPH0338250B2 (en) | ||
| US8343519B2 (en) | Chemical enhancer and method | |
| FR2613227A1 (en) | PHARMACEUTICAL COMPOSITIONS BASED ON MICONAZOLE NITRATE OR ECONAZOLE NITRATE FOR THE TREATMENT OF NAIL FUNGAL INFECTIONS | |
| CN101022779B (en) | Delivery of Antifungal Drugs | |
| JP2001513093A (en) | Topical Nimusulide gel system | |
| PL177710B1 (en) | Topical anti-inflammatory composition, a method for preparing a topical anti-inflammatory composition and a method for dissolving piroxicam | |
| WO2005002561A1 (en) | Antifungal agent composition for external use | |
| JPH02264723A (en) | antifungal agent | |
| JP4442912B2 (en) | Composition for external use | |
| JPH057370B2 (en) | ||
| CN107427582A (en) | External preparation for hyperhidrosis treatment | |
| EP0232830A1 (en) | A composition for the extemporary preparation of formulations for topical applications for pharmaceutical and cosmetic use | |
| JP2009249348A (en) | Water-based adhesive skin patch containing butenafine hydrochloride | |
| JP2006117539A (en) | Oily ointment | |
| JP2003171204A (en) | Gel-type insect repellent preparation | |
| KR20020060171A (en) | Chemical Peeling Agent | |
| JP2003171205A (en) | Gel-type insect repellent preparation | |
| JP2794021B2 (en) | Transdermal preparation containing azelastine or its salts | |
| CA3226113A1 (en) | Topical anesthetic agent-clay composite compositions | |
| JPS59122420A (en) | Local ointment | |
| JP2548686B2 (en) | Topical drug composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2005511357 Country of ref document: JP |
|
| 122 | Ep: pct application non-entry in european phase |